Effect of autologous formalin-fixed tumor vaccine on bone-metastatic breast cancer - A retrospective study

Effect of autologous formalin-fixed tumor vaccine on bone-metastatic breast cancer - A retrospective study - Autologous formalin-fixed tumor vaccine on bone-metastatic breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029726

Enrollment

Registered

2017-10-30

Start date

2004-10-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone-metastatic breast cancer

Interventions

Adjuvant treatment with autologous formalin-fixed tumor vaccine on routine medical care. 3-6 intradermal injections for 6-12 weeks.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Patients whose primary lesion of the breast cancer has been resected before or at the first diagnosis of bone metastasis and who desired adjuvant treatment with AFTV on their own expense. - Outpatient

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Overall survival time (from the date of initial diagnosis of bone metastasis to the date of death)	—

Countries

Japan

Contacts

Public ContactTadao Ohno

Cell-Medicine, Inc. Headquarter

tad-ohno@cell-medicine.com029-828-5591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026